+ Opening

What the files already held.

On 26 August 2021 an FDA investigator began an inspection at Philips Respironics's plant in Murrysville, Pennsylvania. About ten weeks earlier, on 14 June, the company had announced the recall of various models of its ventilators and of its CPAP and BiPAP sleep therapy machines. The devices held a polyester-based polyurethane foam, PE-PUR for short, to reduce sound and vibration, as FDA explains on its page about the recall. FDA adds that the foam can break down and that "black pieces of foam, or certain chemicals that are not visible, could be breathed in or swallowed".

The inspection ran on 21 days and closed on 9 November, when the investigator issued a Form FDA 483, the form on which FDA lists what its investigators observed. In it FDA gives the recalls' cause as "polyester polyurethane foam degradation and volatile organic compound emission" and counts more than 15 million recalled devices. The form itself states the status of its eight observations: "They are inspectional observations, and do not represent a final Agency determination regarding your compliance." The first observation reads "Risk analysis is inadequate", and under it and the observations after it the form sets out what the firm's own files already held.

The form records that the firm learned of the foam's degradation in 2015, and from two sources. The first was its raw foam supplier. Emails with the supplier began on 30 October 2015, and FDA cites them as showing that the firm was made aware of "polyester polyurethane foam degradation issues" in or around October 2015. The second was within Philips: FDA records that on or around 25 November 2015 the firm was aware that another Philips entity had begun preventive maintenance on Trilogy ventilators "in response to foam degradation issues and complaints in the field". In FDA's account the supplier confirmed the issues by email on 5 August 2016, in a reply that "implies that degradation of polyester polyurethane foam is likely".

The form also records that the firm was aware of issues and concerns about potential foam degradation or emissions of volatile organic compounds in "at least fourteen instances, assessments, and/or test reports". They are dated from 1 April 2016 to 22 January 2021, and the earliest of them examine the foam itself. The first examined Trilogy foam from two complaints received in October 2015 and documented "base polymer cleavage and embrittlement": the foam's chains had been cut, and the foam had turned brittle. A report of 30 August 2016 found that "Polyester urethanes show bad resistance against high humidity in combination with high temperature", and a follow-up of 25 November 2016 found that foams of a type whose name the form redacts showed "a far better resistance". A report of December 2018 looked back on "a problem of degradation of the damping foam" in 2016, and one of May 2019 noted that "This chemical reaction can occur if the foam is constantly wet".

Two of the firm's reports, both dated 30 January 2020, turn from the foam to what the machine gives off. Their tests followed ISO 18562-3, the part of the breathing-gas standard on volatile organic compounds, or VOCs. In them a DreamStation 1 device "failed emissions testing for VOCs and Aldehydes", and formaldehyde exceeded its tolerable limits "during initial operation" and at a second point that the form redacts.

The firm's risk assessments weighed what the foam could do to patients. One of 2 July 2020 identified compounds of concern "with potential for carcinogenicity, mutagenicity, and systemic toxicity". One of 10 December 2020 concluded that "the degraded PE-PUR foam is not considered biocompatible". It rested that conclusion in part on "the results of the ISO 10993 testing to include mutagenic responses in both a bacterial and mammalian system". A biocompatibility assessment of 11 January 2021 concurred. Three final laboratory reports that the firm commissioned are dated 13 January 2021. Two judged the foam or its extract "mutagenic", able to cause changes in DNA, and the third found "a cytotoxic potential", a potential to harm mammalian cells grown in culture. The last of the fourteen, dated 22 January 2021, repeated that the degraded foam is "not considered biocompatible".

A device built with silicone foam failed an emissions test as well. The form records the firm's test report of 24 August 2021, in which an A Series CPAP device containing silicone foam failed testing for volatile organic compounds (Chapter 20).

The firm's tests followed the field's own standards: ISO 18562-3 for the emissions, and the ISO 10993 series on the biological evaluation of medical devices for the cells and the mutations. A test result protects patients only once it is carried into a decision about the device's risk, the chain that Chapter 22 follows. That decision rests on the questions of this book: what leaves a material in use, by which route it reaches a patient, how much arrives, what the body does with it, and what a laboratory can measure to see each step before patients meet it.

Created with Claude (Anthropic).
Educational reference material, not engineering, regulatory or clinical advice. Product and company names referenced are the property of their respective owners.